
Moderna, Inc.
MRNAHealthcare|Biotechnology|US
$254.19
+12.73 (+5.27%)
Tangible Book / Share
$17.05
Cash / Share
$12.90
Financials
Financial Snapshot
Market Cap
$101.48B
Enterprise Value
$104.47B
Revenue (TTM)
$2.52B
Net Income (TTM)
-$2.79B
Cash & Investments
$5.17B
Net Cash
$992.0M
Free Cash Flow (TTM)
-$1.95B
Operating CF (TTM)
-$1.76B
Debt/Equity
0.61
Cash Runway & Burn Rate
Cash on Hand
$5.17B
Quarterly Burn
$441.0M
Monthly Burn
$147.0M
Est. Runway
~11.7 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.06B | $756.0M | $1.52B | $1.10B | $4.61B | $10.73B | $9.90B | $8.60B | $7.03B | $5.80B | $5.17B | |
| Operating Cash Flow | $66.7M | -$331.5M | -$330.9M | -$459.0M | $2.03B | $13.62B | $4.98B | -$3.12B | -$3.00B | -$1.87B | -$1.76B | |
| Free Cash Flow | $33.6M | -$389.9M | -$436.6M | -$490.5M | $1.96B | $13.34B | $4.58B | -$3.83B | -$4.05B | -$2.06B | -$1.95B | |
| Capital Expenditure | -$33.1M | -$58.4M | -$105.8M | -$31.6M | -$67.4M | -$284.0M | -$400.0M | -$707.0M | -$1.05B | -$192.0M | -$185.0M | |
| Financing Cash Flow | $472.9M | $168.0K | $1.23B | $51.1M | $2.03B | -$873.0M | -$3.45B | -$1.38B | $56.0M | $593.0M | $3.34B |
R&D Spending
R&D (TTM)
$2.66B
R&D Intensity
105.3%
R&D Growth vs Prior
-15.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.4M | $205.8M | $135.1M | $60.2M | $803.4M | $17.74B | $18.88B | $6.85B | $3.20B | $1.94B | $2.52B | |
| R&D Expense | $274.7M | $410.5M | $454.1M | $496.3M | $1.37B | $1.99B | $3.29B | $4.84B | $4.54B | $3.13B | $2.66B | |
| R&D % of Revenue | 253.4% | 199.4% | 336.2% | 824.3% | 170.6% | 11.2% | 17.5% | 70.8% | 142.0% | 161.1% | 105.3% | |
| SG&A | $57.5M | $64.7M | $94.3M | $109.6M | $188.3M | $567.0M | $1.13B | $1.55B | $1.17B | $1.02B | $979.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.4M | $205.8M | $135.1M | $60.2M | $803.4M | $17.74B | $18.88B | $6.85B | $3.20B | $1.94B | $2.52B | |
| Cost of Revenue | $15.1M | $20.5M | $24.9M | $31.0M | $39.2M | $2.62B | $5.42B | $4.69B | $1.46B | $868.0M | $1.82B | |
| Gross Profit | $93.3M | $185.3M | $110.2M | $29.2M | $764.2M | $15.12B | $13.46B | $2.15B | $1.74B | $1.08B | $707.0M | |
| R&D | $274.7M | $410.5M | $454.1M | $496.3M | $1.37B | $1.99B | $3.29B | $4.84B | $4.54B | $3.13B | $2.66B | |
| SG&A | $57.5M | $64.7M | $94.3M | $109.6M | $188.3M | $567.0M | $1.13B | $1.55B | $1.17B | $1.02B | $979.0M | |
| Operating Income | -$223.8M | -$269.4M | -$468.9M | -$545.7M | -$763.1M | $13.30B | $9.42B | -$4.24B | -$3.94B | -$3.07B | -$2.93B | |
| Interest Expense | $0.00 | $132.0K | $3.1M | $6.6M | $9.9M | $18.0M | $29.0M | $38.0M | $24.0M | $10.0M | $25.0M | |
| Pretax Income | -$215.2M | -$256.0M | -$440.0M | -$514.7M | -$744.5M | $13.29B | $9.57B | -$3.94B | -$3.61B | -$2.77B | -$2.73B | |
| Net Income | -$216.2M | -$255.9M | -$384.7M | -$514.0M | -$747.1M | $12.20B | $8.36B | -$4.71B | -$3.56B | -$2.82B | -$2.79B | |
| EPS (Diluted) | -3.79 | -0.72 | -1.17 | -1.55 | -1.96 | 28.29 | 20.10 | -12.34 | -9.27 | -7.26 | -7.09 | |
| EBITDA | -$208.7M | -$235.3M | -$412.1M | -$477.1M | -$703.6M | $13.54B | $9.95B | -$3.28B | -$3.39B | -$2.55B | -$2.46B | |
| Shares Out. (M) | 64.09 | 376.00 | 328.80 | 330.80 | 381.33 | 431.00 | 416.00 | 382.00 | 384.00 | 389.00 | 430.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.1M | $134.9M | $658.4M | $235.9M | $2.62B | $6.85B | $3.21B | $2.91B | $1.93B | $2.60B | $1.20B | |
| Short-Term Investments | $1.01B | $621.2M | $863.1M | $867.1M | $1.98B | $3.88B | $6.70B | $5.70B | $5.10B | $3.20B | $3.98B | |
| Total Current Assets | $1.09B | $783.2M | $1.56B | $1.13B | $6.30B | $16.07B | $13.43B | $10.32B | $8.10B | $6.54B | $7.34B | |
| Total Assets | $1.42B | $1.08B | $1.96B | $1.59B | $7.34B | $24.67B | $25.86B | $18.43B | $14.14B | $12.34B | $13.47B | |
| Total Current Liabilities | $162.8M | $191.5M | $222.8M | $143.1M | $4.39B | $9.13B | $4.92B | $3.02B | $2.21B | $1.99B | $2.03B | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.24B | $3.55B | |
| Total Liabilities | $575.3M | $459.2M | $431.9M | $414.6M | $4.78B | $10.52B | $6.74B | $4.57B | $3.24B | $3.69B | $6.63B | |
| Stockholders' Equity | $841.9M | $625.3M | $1.53B | $1.17B | $2.56B | $14.14B | $19.12B | $13.85B | $10.90B | $8.65B | $6.84B | |
| Retained Earnings | -$365.7M | -$621.9M | -$1.01B | -$1.50B | -$2.24B | $9.96B | $18.32B | $13.61B | $10.04B | $7.22B | $5.26B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $66.7M | -$331.5M | -$330.9M | -$459.0M | $2.03B | $13.62B | $4.98B | -$3.12B | -$3.00B | -$1.87B | -$1.76B | |
| Capital Expenditure | -$33.1M | -$58.4M | -$105.8M | -$31.6M | -$67.4M | -$284.0M | -$400.0M | -$707.0M | -$1.05B | -$192.0M | -$185.0M | |
| Free Cash Flow | $33.6M | -$389.9M | -$436.6M | -$490.5M | $1.96B | $13.34B | $4.58B | -$3.83B | -$4.05B | -$2.06B | -$1.95B | |
| Investing Cash Flow | -$648.6M | $416.1M | -$372.5M | -$14.9M | -$1.67B | -$8.52B | -$5.18B | $4.21B | $1.95B | $1.95B | -$1.51B | |
| Financing Cash Flow | $472.9M | $168.0K | $1.23B | $51.1M | $2.03B | -$873.0M | -$3.45B | -$1.38B | $56.0M | $593.0M | $3.34B | |
| Issuance of Stock | $0.00 | $212.0K | $1.23B | $47.3M | $2.04B | $124.0M | $65.0M | $46.0M | $66.0M | $35.0M | $188.0M | |
| Repurchase of Stock | $0.00 | $0.00 | -$8.2M | $2.9M | $0.00 | -$857.0M | -$3.33B | -$1.15B | $0.00 | $0.00 | -$2.0M | |
| Net Debt Issuance | $0.00 | $1.4M | $9.5M | $1.0M | -$6.0M | -$140.0M | -$184.0M | -$270.0M | -$10.0M | $539.0M | $3.54B | |
| Stock Based Comp. | $39.4M | $40.1M | $72.6M | $81.1M | $93.0M | $142.0M | $226.0M | $305.0M | $429.0M | $483.0M | $351.0M | |
| Net Change in Cash | -$109.0M | $84.8M | $523.5M | -$422.8M | $2.39B | $4.22B | -$3.64B | -$289.0M | -$999.0M | $668.0M | $61.0M |
Dilution Tracker
Shares Outstanding
399M
5-Year Share Growth
+2.0%
Stock Issuance (TTM)
$188.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 64.09 | 376.00 | 328.80 | 330.80 | 381.33 | 431.00 | 416.00 | 382.00 | 384.00 | 389.00 | 430.00 | |
| Change vs Prior % | — | 486.6% | -12.6% | 0.6% | 15.3% | 13.0% | -3.5% | -8.2% | 0.5% | 1.3% | 10.5% | |
| Stock Issuance | $0.00 | $212.0K | $1.23B | $47.3M | $2.04B | $124.0M | $65.0M | $46.0M | $66.0M | $35.0M | $188.0M | |
| Stock Repurchase | $0.00 | $0.00 | -$8.2M | $2.9M | $0.00 | -$857.0M | -$3.33B | -$1.15B | $0.00 | $0.00 | -$2.0M | |
| Stock Based Comp. | $39.4M | $40.1M | $72.6M | $81.1M | $93.0M | $142.0M | $226.0M | $305.0M | $429.0M | $483.0M | $351.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 86.1% | 90.0% | 81.6% | 48.5% | 95.1% | 85.2% | 71.3% | 31.5% | 54.2% | 55.3% | 28.0% | |
| Operating Margin % | -206.4% | -130.9% | -347.1% | -906.4% | -95.0% | 75.0% | 49.9% | -61.9% | -123.3% | -158.1% | -116.0% | |
| Net Margin % | -199.5% | -124.3% | -284.8% | -853.7% | -93.0% | 68.8% | 44.3% | -68.8% | -111.3% | -145.2% | -110.5% | |
| EBITDA Margin % | -192.5% | -114.3% | -305.1% | -792.4% | -87.6% | 76.3% | 52.7% | -47.9% | -106.1% | -131.3% | -97.2% | |
| FCF Margin % | 31.0% | -189.4% | -323.3% | -814.7% | 243.9% | 75.2% | 24.3% | -55.9% | -126.8% | -106.2% | -77.2% | |
| ROE % | -25.7% | -40.9% | -25.1% | -43.8% | -29.2% | 86.3% | 43.7% | -34.0% | -32.7% | -32.6% | -37.6% | |
| ROA % | -15.3% | -23.6% | -19.6% | -32.3% | -10.2% | 49.5% | 32.3% | -25.6% | -25.2% | -22.9% | -20.7% | |
| ROIC % | -17.8% | -30.2% | -27.0% | -37.7% | -25.6% | 77.5% | 38.9% | -27.5% | -32.5% | -29.7% | -25.6% | |
| R&D / Revenue % | 253.4% | 199.4% | 336.2% | 824.3% | 170.6% | 11.2% | 17.5% | 70.8% | 142.0% | 161.1% | 105.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 89.9% | -34.4% | -55.4% | 1234.3% | 2107.6% | 6.4% | -63.7% | -53.3% | -39.2% | |
| Gross Profit | 0.0% | 98.6% | -40.5% | -73.5% | 2518.2% | 1878.4% | -11.0% | -84.0% | -19.5% | -38.0% | |
| Operating Income | 0.0% | -20.4% | -74.1% | -16.4% | -39.8% | 1842.3% | -29.2% | -145.0% | 6.9% | 22.1% | |
| Net Income | 0.0% | -18.4% | -50.3% | -33.6% | -45.3% | 1733.3% | -31.5% | -156.4% | 24.5% | 20.8% | |
| EPS (Diluted) | 0.0% | 81.0% | -62.5% | -32.5% | -26.5% | 1543.4% | -29.0% | -161.4% | 24.9% | 21.7% | |
| Operating Cash Flow | 0.0% | -596.7% | 0.2% | -38.7% | 541.6% | 571.9% | -63.4% | -162.6% | 3.7% | 37.6% | |
| Free Cash Flow | 0.0% | -1260.7% | -12.0% | -12.3% | 499.5% | 580.6% | -65.6% | -183.5% | -6.0% | 49.1% | |
| R&D Expense | 0.0% | 49.4% | 10.6% | 9.3% | 176.1% | 45.3% | 65.5% | 47.0% | -6.2% | -31.1% | |
| SG&A Expense | 0.0% | 12.7% | 45.6% | 16.3% | 71.7% | 201.2% | 99.6% | 36.8% | -24.2% | -13.3% | |
| Total Assets | 0.0% | -23.5% | 80.9% | -19.0% | 361.6% | 236.2% | 4.8% | -28.7% | -23.2% | -12.8% | |
| Book Value / Share | 0.0% | -87.3% | 179.8% | -23.7% | 89.1% | 422.6% | 38.3% | -25.3% | -21.7% | -21.7% | |
| Debt | 0.0% | 25.5% | 113.5% | 295.2% | 79.1% | 286.5% | 31.0% | 3.6% | -39.9% | 156.5% | |
| Diluted Shares | 0.0% | 486.6% | -12.6% | 0.6% | 15.3% | 13.0% | -3.5% | -8.2% | 0.5% | 1.3% |
Valuation
P/E (TTM)At Loss
P/S40.19
10Y Low / Med / High3.75 / 11.00 / 107.47
P/B14.91
10Y Low / Med / High1.33 / 3.70 / 15.56
EV/EBITDAAt Loss
EV/Revenue41.37
10Y Low / Med / High3.64 / 10.65 / 105.75
P/FCFAt Loss
10Y Low / Med / High7.68 / 20.33 / 35.49
Intrinsic Value Models (per share)
Tangible Book / Share
$17.05
Net Current Assets / Share
$1.79
Cash / Share
$12.90
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -4.91 | -25.83 | -13.05 | -12.62 | -53.30 | 8.38 | 8.45 | -8.06 | -4.49 | -4.06 | -35.95 | |
| P/S Ratio | 11.00 | 33.98 | 37.17 | 107.47 | 49.59 | 5.77 | 3.75 | 5.55 | 4.99 | 5.90 | 40.19 | |
| P/B Ratio | 1.42 | 11.18 | 3.28 | 5.51 | 15.56 | 7.24 | 3.70 | 2.74 | 1.46 | 1.33 | 14.91 | |
| EV/EBITDA | -5.53 | -29.21 | -10.67 | -13.35 | -53.23 | 7.12 | 6.91 | -11.06 | -4.36 | -4.23 | -42.55 | |
| EV/Revenue | 10.65 | 33.40 | 32.55 | 105.75 | 46.62 | 5.44 | 3.64 | 5.30 | 4.62 | 5.55 | 41.37 |
Analyst Estimates & Quality
Altman Z-Score
9.73
Safe
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $2.10B | $2.43B | $3.38B |
| Net Income | -$3.27B | -$1.77B | -$1.06B |
| EPS | $-8.42 | $-4.76 | $-2.85 |
| # Analysts (EPS) | 15 | 15 | 14 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Messenger RNA (mRNA) Medicines | $803.4M | $18.47B | $19.26B | $6.85B | — | — |
| Collaboration Arrangement | — | — | — | — | $12.0M | — |
| Grant | — | — | — | — | $37.0M | — |
| Product Sales | — | — | — | — | $4.52B | — |
| COVID | — | — | — | — | — | $1.81B |
| RSV | — | — | — | — | — | $8.0M |
| Grant revenue | — | — | — | — | — | $22.0M |
| Collaboration revenue | — | — | — | — | — | $13.0M |
| Licensing and royalty revenue | — | — | — | — | — | $11.0M |
| Stand-ready manufacturing revenue | — | — | — | — | — | $80.0M |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Rest Of The World | $38.9M | $5.45B | $7.30B | $3.60B | $810.0M | $603.0M |
| UNITED STATES | $764.5M | $6.18B | $5.15B | $1.90B | $1.78B | $1.20B |
| Europe | — | $6.85B | $6.82B | $1.35B | $598.0M | $53.0M |